medigraphic.com

2010, Número 6

Rev Med Inst Mex Seguro Soc 2010; 48 (6)


Respuesta inmune rápida contra la hepatitis B mediante esquema acelerado de vacunación intradérmica

Solórzano-Santos F, Pérez-de la Cruz L, Meléndez-Blanco SP, Álvarez-y Muñoz MT, Huerta-García GC, Miranda-Novales MG, Vázquez-Rosales G

Idioma: Español
Referencias bibliográficas: 30
Paginas: 603-606
Archivo PDF: 32.87 Kb.


RESUMEN

Objetivo: evaluar los niveles séricos de anticuerpos contra el virus de la hepatitis B en personal de salud que recibió un esquema acelerado por vía intradérmica con microdosis de la vacuna recombinante.
Métodos: estudio cuasiexperimental sin grupo control en trabajadores de la salud sanos no inmunizados contra el virus de la hepatitis B. Se aplicaron tres dosis de 5 µg (0.25 mL) de vacuna intradérmica a las semanas 0, 2 y 4. Se tomó una muestra sérica de 5 mL al ingreso, 2 y 8 semanas después de iniciado el esquema. Los anticuerpos contra el antígeno de superficie del virus de la hepatitis B (antiHB) se cuantificaron por el método de ELISA.
Resultados: se estudiaron 51 individuos negativos para antiHB, 61 % de sexo femenino, edad promedio de 33.5 años. Después de la primera dosis 29 % mostró seroprotección (mediana de 312 mUI/mL), al final del esquema 93 % tuvo antiHB y 78 % alcanzó niveles › 10 mUI/mL.
Conclusiones: con el esquema acelerado de vacunación se alcanza seroconversión en 90 % de los individuos inmunizados. Este esquema induce una inmunidad rápida por lo que podría ser útil en posexposición.

REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997;336:196-204.

  2. Centers for Disease Control and Prevention. Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR 2003;52(36): 868-870. Disponible en http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5236a5.htm

  3. Román S, Panduro A, Aguilar-Gutiérrez Y, Maldonado M, Vázquez-Vandyck M, Martínez-López E, et al. A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review. Hepatol Int 2009;3 (2):343-355.

  4. Chiquete E, Sánchez LV, Becerra G, Quintero A, Maldonado M, Panduro A. Performance of the serologic and molecular screening of blood donations for the hepatitis B and C viruses in a Mexican transfusion center. Ann Hepatol 2005; 4(4):275-278.

  5. Tanaka J. Hepatitis B epidemiology in Latin America. Vaccine 2000;18(Supl 1): S17-S19.

  6. Kershenobich D, Hurtado R, Collawn C, Bobadilla J, Cabrera G, Borovoy J, et al. Seroprevalence of viral markers of hepatitis B among health professionals. Multicenter study in Mexico. Rev Invest Clin 1990;42(4):251-256.

  7. Flores-Calderón J, Álvarez-Muñoz MT, Bustamante-Calvillo ME, Vázquez-Rosales G, Reyes-Morales H. Prevalencia de marcadores serológicos para el virus de la hepatitis B en el hospital pediátrico. Bol Med Hosp Infant Mex 1994;51(2):99-104.

  8. Roome AJ, Walsh SJ, Cartter ML , Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270(24):2931-2934.

  9. Navarrete-Navarro S, Álvarez-Muñoz MT, Bustamante-Calvillo ME, Vallejo- Aguilar OJ, Muñoz O, Santos-Preciado JI, Ávila-Figueroa C. Protection of health personnel against hepatitis B by DNA recombinant vaccine. Bol Med Hosp Infant Mex 1992;49(1):739-742.

  10. Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, Looke DF, et al. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 2002;23(2):87- 90.

  11. Margolis HS, Presson AC. Host factors related to poor immunogenicity of hepatitis B vaccine in adults. JAMA 1993;270(24):2971-2972.

  12. Connor BA, Blatter MM, Beran J, Zou B, Trofa AF. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J Travel Med 2007;14:9-15.

  13. Saltoglu N, Inal AS, Tasova Y, Kandemir O. Comparison of the accelerated and classic vaccination schedules against hepatitis B: three-week hepatitis B vaccination schedule provides immediate and protective immunity. Ann Clin Microbiol Antimicrob 2003;2:10. Disponible en http://www.ncbi.nlm.nih. gov/pmc/articles/PMC293476/

  14. Wahl M, Hermodsson S, Iwarson S. Hepatitis B vaccination with short dose intervals. A possible alternative for post-exposure prophylaxis? Infection 1988; 16(4):229-232.

  15. Leonardi S, Barone P, Musumeci S. Intradermal hepatitis B vaccination: fiveyear follow-up. Pediatr Infect Dis J 1995;14(8):716-717.

  16. Vázquez G, Mendoza-Guevara L, Álvarez T, Aguilar A, Morales A, Rodríguez F, et al. Comparison of the response to the recombinant vaccine against hepatitis B virus in dialyzed and nondialyzed children with CRF using different doses and routes of administration. Adv Perit Dial 1997;13:291-296.

  17. Miller KD, Gibbs RD, Mulligan MM, Nutman TB, Francis DP. Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet 1983;2(8365-8366):1454-1456.

  18. Zuckerman AJ. Appraisal of intradermal immunization against hepatitis B. Lancet 1987;1(8530): 435-436.

  19. Halsey NA, Reppert EJ, Margolis HS, Francis DP, Fields HA. Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine 1986;4(4):228- 232.

  20. Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A. Comparison of higherdose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 2000;21 (4):264-269.

  21. McMaster KR, Roper JK, Carter JB. Intradermal hepatitis B vaccination in a 300-bed primary care hospital: experience with a recombinant vaccine in a four-dose schedule. Am J Infect Control 1993; 21(6):283-288.

  22. Yamashiki M, Kosaka Y, Nishimura A. An effective intradermal hepatitis B vaccination. Vaccine 1997;15(15):1618-1623.

  23. Kyi KP, Oo KM, Htun MM, Tun WM, Aye KK, Oo SS, et al. Clinical trial of the intradermal administration of hepatitis B vaccine produced at the Department of Medical Research, Myanmar. Vaccine 2002;20(11-12):1649-1652.

  24. Kurugöl Z, Erensoy S, Aksit S, Egemen A, Bilgic A. Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year followup study. Vaccine 2001;19(28-29):3936-3939.

  25. Wiström J, Settergren B, Gustafsson A, Juto P, Norrby RS. Intradermal vs. intramuscular hepatitis B vaccinations. JAMA 1990;264(2):181-182.

  26. Ghabouli MJ, Sbouri AH, Shoeibi N, Bajestan SN, Baradaran H. High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. Eur J Epidemiol 2004;19(9):871-875.

  27. Osorio JE, Zuleger CL, Burger M, Chu Q, Payne LG, Chen D. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol 2003;81(1):52-58.

  28. Chau KF, Cheng YL, Tsang DN, Choi KS, Wong KM, Chak WL, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis 2004;43(5):910-917.

  29. Elisbão Mdo C, Baldy JL, Bonametti AM, Reiche EM, Morimoto HK, Pontello R, et al. Intradermal vaccination of adults with three low doses (2 micrograms) of recombinant hepatitis B vaccine. II. Persistence of immunity and induction of immunologic memory. Mem Inst Oswaldo Cruz 2003;98(8):1109-1113.

  30. Baldy JL, Elisbao Mdo C, Anzai ET, Pontello R, Reiche EM, Zaha-Inouye MM, et al. Intradermal vaccination of adults with three low doses (2 micrograms) of recombinant hepatitis B vaccine. I. Seroconversion rate and adverse effects. Mem Inst Oswaldo Cruz 2003;98(8):1101-1107.

2020     |     www.medigraphic.com